Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) was the target of a significant growth in short interest in January. As of January 12th, there was short interest totalling 2,605,402 shares, a growth of 0.1% from the December 29th total of 2,603,929 shares. Based on an average daily trading volume, of 340,021 shares, the days-to-cover ratio is currently 7.7 days. Approximately 8.2% of the company’s stock are short sold.
A number of research firms have commented on AST. Zacks Investment Research cut shares of Asterias Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 19th. HC Wainwright set a $11.00 price objective on shares of Asterias Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. Asterias Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $8.94.
Asterias Biotherapeutics (NYSEAMERICAN:AST) traded down $0.06 during mid-day trading on Tuesday, reaching $2.14. 179,042 shares of the company’s stock were exchanged, compared to its average volume of 289,127. Asterias Biotherapeutics has a 1 year low of $1.95 and a 1 year high of $4.35. The company has a market capitalization of $121.90, a PE ratio of -3.54 and a beta of 1.30.
Asterias Biotherapeutics (NYSEAMERICAN:AST) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.15) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.15). Asterias Biotherapeutics had a negative net margin of 403.38% and a negative return on equity of 79.80%.
COPYRIGHT VIOLATION NOTICE: “Short Interest in Asterias Biotherapeutics Inc (AST) Expands By 0.1%” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/30/short-interest-in-asterias-biotherapeutics-inc-ast-expands-by-0-1.html.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.